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Abstract
Background: Bronchiectasis is frequently associated (up to 30%) with chronic inflammatory rheumatic diseases and
leads to lower respiratory tract infections. Data are lacking on the risk of lower respiratory tract infections in
patients treated with biologic agents.
Methods: Monocenter, retrospective systematic study of all patients with a chronic inflammatory rheumatic disease
and concomitant bronchiectasis, seen between 2000 and 2009. Univariate and multivariate analyses were
performed to evidence predictive factors of the number of infectious respiratory events.
Results: 47 patients were included (mean age 64.1 ± 9.1 years, 33 (70.2%) women), with a mean follow-up per
patient of 4.3 ± 3.1 years. Rheumatoid arthritis was the main rheumatic disease (90.1%). The mean number of
infectious events was 0.8 ± 1.0 event per patient-year. The factors predicting infections were the type of treatment
(biologic vs. non biologic disease-modifying treatments), with an odds ratio of 8.7 (95% confidence interval: 1.7-
43.4) and sputum colonization by any bacteria (odds ratio 7.4, 2.0-26.8). In multivariate analysis, both factors were
independently predictive of infections.
Conclusion: Lower respiratory tract infectious events are frequent among patients receiving biologics for chronic
inflammatory rheumatic disease associated with bronchiectasis. Biologic treatment and pre-existing sputum
colonization are independent risk factors of infection occurrence.
Background
Biologic disease-modifying treatments have introduced a
new era of disease control in inflammatory rheumatic
diseases. However, non biologic disease-modifying anti-
rheumatic drugs (DMARDs) and more so, biologics,
including tumor necrosis factor (TNF) inhibitors, seem
to increase the risk of infectious events [1-3]. Several stu-
dies in particular issued from randomised trials, indicated
that the infection rate was up to two fold higher among
rheumatoid arthritis (RA) patients receiving TNF inhibi-
tors compared with those receiving methotrexate alone.
However, this increase in risk is not consistently reported
[4,5]. Infections during rituximab or abatacept treatment
may also be increased, although this increase was not sig-
nificant in a meta-analysis [6]. Infections occurring with
biologics (especially TNF inhibitors) often also concern
the lower respiratory tract [3]. In patients with RA, irre-
spective of the treatment, infections frequently concern
the respiratory tract [7] and pre-existing chronic lung
disease was one of the strong predictors of infections [8].
Bronchiectasis is defined by an irreversible airway dilata-
tion with chronic bronchial inflammation [9]. Sputum and
chronic cough are the main clinical features. The diagnosis
is confirmed by high resolution computed tomography
scans. Patients with bronchiectasis suffer from recurrent
acute exacerbations, which may require hospitalization
[10,11]. The exact prevalence of bronchiectasis is unknown,
[12] but probably underestimated because of the confusion
with chronic bronchitis and the lack of systematic investi-
g a t i o n s .T h ep r e v a l e n c ei se s t i m a t e da r o u n d1c a s ei n1 , 0 0 0
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any medium, provided the original work is properly cited.adults in the United Kingdom [13]. Bronchiectasis occurs
in bronchial obstruction (broncholithiasis), bronchial
stenosis from infections (tuberculosis) and foreign body
aspiration but may also be the main feature of pulmonary
diseases as cystic fibrosis or associated with systemic dis-
eases (primary ciliary dyskinesia, immunodeficiency states,
alpha 1 antitrypsin deficiency, inflammatory bowel disease
and rheumatic diseases, in particular RA) [14,15]. The pre-
valence of bronchiectasis in RA has been evaluated by high
resolution computed tomography in small studies [16-19]:
the prevalence was very high since bronchiectasis was evi-
denced in 18 to 30% of patients.
Taken together, these observations suggest a potential
increased risk of infections of lower respiratory tract in
patients with chronic rheumatic disorders treated with
biologic DMARDs. The objective of this study was to eval-
uate the risk of lower respiratory tract infectious events
among patients followed for bronchiectasis and receiving
non biologic DMARDs and/or biologic treatments for
rheumatic diseases, and to assess factors associated with
infections, and in particular disease-modifying treatments.
Methods
Study design
Monocenter, investigator-initiated, systematic retrospec-
tive study.
Patient selection
All in and outpatients from one tertiary rheumatology
department (Cochin Hospital) seen between January 2000
and July 2009 were screened through a full-text search of
the computerized database of patients’ files (using the key
words ["rheumatoid arthritis” or “systemic erythematosus
lupus” or “ankylosing spondylitis"] AND “bronchiectasis”).
Data were censored before 2000 due to the absence of bio-
logics before that date. Patients were included in the pre-
sent study if (a) they had a definite diagnosis of an
inflammatory rheumatic disorder (American Rheumatism
Association criteria for RA [20] and for systemic lupus
erythematosus [21,22], and Amor’s criteria [23] for spon-
dylarthritis), (b) they had definite bronchiectasis, and (c)
they were exposed to at least one non biologic DMARD
and/or biologic treatment for their rheumatic disease
during at least three months with a duration of follow-up
in the department, subsequent to the diagnosis of
bronchiectasis.
Non biologic DMARDs included methotrexate, lefluno-
mide, azathioprine, ciclosporine, hydroxychloroquine,
sulfasalazine, penicillamine, cyclophosphamide and gold
salts. Biologic DMARDs included TNF inhibitors (etaner-
cept, adalimumab and infliximab), rituximab, abatacept
and tocilizumab. Drug selection was made by the medical
staff, according to usual practice and based on the most
recent published data concerning rheumatic diseases
management.
A diagnosis of bronchiectasis according to expert opi-
nion based on high resolution computed tomography
scan abnormalities required that at least two different air-
ways in areas of non-consolidated lung met one or more
of the following criteria [12]: (a) inner diameter of airway
lumen larger than the diameter of the accompanying pul-
monary artery, (b) airway visible within 1 cm of pleural
edge/chest wall, (c) non-tapering of airway for at least 2
cm beyond last branch point. All patients included in the
study had a high resolution computed tomography scan.
Others pulmonary investigations were performed accord-
ing to the physician in charge. Recent infection of lower
respiratory tract before the diagnosis of bronchiectasis
was an exclusion criteria because of well known transient
bronchiectatic changes seen on CT scans after an episode
of pneumonia.
Global data collection
Data were collected by 2 investigators (GG and SD),
based on the computerised file and if necessary the paper
file, using a standardised extraction form. Data collected
were: age, sex, date of diagnosis, type and characteristics
of the rheumatic disease (for RA: rheumatoid factor sta-
tus, anti-cyclic citrullinated peptide antibodies, and ero-
siveness yes/no, and for spondylarthritis, HLA B27
status). For bronchiectasis, date of diagnosis, underlying
related systemic disease, tobacco consumption and pre-
existing bacteriologic colonisation were collected. Spu-
tum bacteriologic colonisation was collected at the first
period of treatment of the study and during each treat-
ment period in detail (by bacterium) and analysed as:
none, or at least one bacterium. Moreover, pneumologist
opinion was collected in patients’ files regarding the
potential relationship between bronchiectasis and the
rheumatic disease. All the HRCT were reviewed with a
radiologist.
Infectious event definition and rate
An infectious event was defined as change in sputum pro-
duction, increased dyspnea, increased cough, fever,
increased wheezing, malaise, radiographic changes consis-
tent with a new pulmonary process, changes in chest
sounds and reduced pulmonary function [24]. Only infec-
tious events necessitating prescription of antibiotics for
pulmonary purposes were recorded. Infections in bronch-
iectasis are usually defined. Sputum quality was checked
with Geckler classification [25]: only suptum Geckler 5
were kept.
Infectious events were reported by treatment of rheu-
matic disease period, as events per patient-year. Each
patient could thus be analysed several times, according to
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analysed by treatment period distinguishing non biologic
DMARDs (pooled) versus biologics (pooled). Among bio-
logic treatments, infectious rates were reported for each
biologic for descriptive purposes but the rates were not
compared statistically due to the small sample size.
Statistical analysis
Patients’ characteristics were reported as number (percen-
tage) for categorical variables and mean ± standard devia-
tion (SD) for continuous variables. The primary outcome
was the rate of infections per patient-year. This rate was
calculated as infectious events per patient-year of follow-
up: the number of events was divided by (number of
months of follow-up/12). The date for inclusion was
defined as the first follow-up posterior to 2000, or prior to
the diagnosis of bronchiectasis, as applicable. The end of
s t u d yd a t ew a sd e f i n e da st h el a s tf o l l o w - u pd a t ei no u r
centre, or the censoring date (data collection, i.e., July
2009).
To evidence predictive factors of infections, 2 separate
analyses by univariate then multivariate logistic regressions
were performed. (a) At the patient level, the dependent
variable was the number of infections per patient-year
above the mean for all patients (i.e., > 0.8 infectious events
per patient-year of follow-up) and explanatory variables
were age, sex, rheumatic disease type and duration,
bronchiectasis disease duration, and number of previous
DMARDs (non biologic or biologic). (b) At the treatment
period level, the dependent variable was the number of
infections per patient-year above the mean for all periods
(i.e., > 0.8 infectious events per patient-year of follow-up)
and explanatory variables were DMARD type (non biolo-
gic DMARD versus biologic), steroid intake and steroid
dose, sputum colonisation during the treatment period
(yes/no) and number of previous biologic treatments. In
the multivariate logistic regression analyses, all variables
with a p value <0.20 in univariate analyses were entered
into the model. Linear regression was also performed to
find predictive factors of the number of infectious events.
Results were similar to the logistic regression results (data
not shown). For all statistical analyses, a p-value less than
0.05 was considered statistically significant. Statistical ana-
lyses involved use of the SAS release 9.1 statistical software
package.
Results
Selection process and follow-up
Among the 6,548 patients seen in the department
between 2000 and 2009 for suspected inflammatory rheu-
matic diseases, bronchiectasis was mentioned in the com-
puterized file in 140 cases (Figure 1). Finally, 47 patients
were included in the study (Figure 1). These 47 patients
totalised 98 periods of treatment with a mean duration of
treatment period of 2.1 ± 2.2 years. The mean follow-up
per patient was 4.3 ± 3.1 years (range, 3 months to 13.5
years); thus, the total data concerned 194 patient-years of
follow-up.
Baseline characteristics of patients (Table 1)
For the 47 patients included, mean age at inclusion was
64.1 ± 9.1 years and 33 (70.2%) were females.
The main underlying rheumatic disease was RA (40
patients, 85.1%), 4 (8.5%) had spondylarthritis; 1 (2.1%)
had systemic lupus erythematosus and 5 (10.6%) had
another underlying rheumatic disease (2 patients with
SAPHO [synovitis, acne, palmoplantar pustulosis, hyper-
ostosis, and osteitis] and 3 patients with an unclassified
inflammatory rheumatic disease). Among the RA
patients, 27 (79.4% of available data) had typical radio-
graphic erosions. Anti-cyclic citrullinated protein anti-
bodes and rheumatoid factor were noted in 12 (80% of
available data) and 35 (100% of available data) patients,
respectively. Among the 4 spondylarthritis patients, 3
were HLA B27 positive (100% of available data).
Bronchiectasis mean duration at inclusion in the study
for all patients was 6.4 ± 15.9 years (range 0; 68 yrs), 27
(60%) appeared after the rheumatic disease, and 13 (37% of
available data) were related to RA. Bronchiectasis not
related to RA was due to infectious respiratory events in
childhood in all cases. No case of cystic fibrosis or others
congenital disorders were observed. Bronchiectasis was
described on high resolution computed tomography as dif-
fuse in all cases but 2 (95.7%) patients. Bronchiectasis was
moderate in most patients (40/47; 85%); it was associated
with other radiological patterns i.e., bronchial wall thicken-
ing and bronchiolitis signs (air trapping, centrolobular
micronodules) in 10 and 6 cases, respectively. No specific
pharmacologic treatment was needed for bronchiectasis,
before the diagnosis of rheumatic disease. Five patients had
bacteriologic colonisation during the first period of
DMARD treatment: there was 1 single colonisation with
Pseudomonas aeruginosa, 1 single colonisation with Sta-
phylococcus aureus and 1 with Haemophilus Influenzae; 2
patients had mixed colonisation (Pseudomonas aeruginosa
and Staphylococcus aureus in one case and Pseudomonas
aeruginosa and Haemophilus Influenzae in the other case).
Colonisation appeared for the first time at the second per-
iod of treatment in one patient (Pseudomonas aeruginosa)
and at the third period of treatment in one patient (Pseudo-
monas aeruginosa and Haemophilus Influenzae).N e wb a c -
teria were found in already positive sputum patients in 2
cases. No colonisation was noted in 61 periods, i.e., 32
patients. Data were not available in 19 periods (6 patients).
All patients were screened for mycobacterial infections:
none was evidenced in the study. Tobacco consumption
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smokers. Smoking was given up for 22 (15; 28) years in ex-
smokers patients.
Among the 98 periods of treatment, there were 58 peri-
ods of biologic treatment (Table 2) and 40 periods of non
biologic DMARD treatment (16 with methotrexate alone,
16 with leflunomide alone and 8 with associations or
other non biologic DMARDs including hydroxychloro-
quine, sulfasalazine, penicillamine, azathioprine, cyclo-
phosphamide, gold salts, cyclosporine). The median dose
Patients seen at least once between 2000 and 2009  
with inflammatory diseases mentioned in computerised file: 
RA N=3,415 
Spondylarthritis N=2,494  
Systemic lupus erythematosus N=191 
Other N=448 
Bronchiectasis mentioned in patient’s computerised file: N=140 
 
Patients excluded N=54 
No bronchiectasis N=33 
No chronic inflammatory rheumatic disease 
N=21 
Definite bronchiectasis and chronic 
inflammatory rheumatic disease N=86 
 
Lack of follow up N=39 
Insufficient follow up N=38 
Not followed up in the department N=1 
Patients included in the study N=47 
RA N= 40 
Spondylarthritis N= 4 
Systemic lupus erythematosus N= 1 
Other N= 5 
Figure 1 Flow Chart of patient selection to collect all patients in one centre treated with either DMARDs or biologics for a rheumatic
disease, and with concomitant bronchiectasis, with a follow-up of at least 3 months in our centre.
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respiratory tract infections compared to those without
lower respiratory tract infections (6 [5-9.5] vs. 7 [5-10]
mg/d; p = 0.67).
Infection rate and predictive factors
Among the 47 patients, a total of 93 infections was noted,
i.e., a mean of 0.8 ± 1.0 infectious events per patient-year
of follow-up for all patients (range 0-4.3). Nine cases of
respiratory tract infections occurring in 8 patients necessi-
tated hospitalization (of whom, one patient was hospita-
lized in an intensive care unit for acute respiratory
distress). In all the other cases, the infection was treated in
outpatients. Most of the infectious events 92/93 (98.9%)
occurred in RA patients. Bacterium causing infectious
events of the lower respiratory tract were the same pre-
viously found in pre-existing colonized sputum.
At the patient level, no variable (age, sex, underlying
rheumatic disease type and duration, bronchiectasis disease
duration and number of previous DMARDs) was predictive
of infections. Analyses were performed to explain the num-
ber of infectious events per period: above or below the
mean (0.8 per treatment period). In univariate analysis,
only 2 factors were predictive of infections. Biologics were
associated with more infections than non biologic
DMARDs (1.2 ± 1.6 vs. 0.2 ± 0.5 infections per patient-
year; p = 0.001). Colonisation at the beginning of the study
period was also predictive of infections (0.5 ± 1.0 vs.
2.5 ± 1.7 infections per patient-year; p = 0.0001). In multi-
variate analysis, both factors were independently predictive
of infections (Table 3). The odds ratio for infections with
versus without biologics was 8.7 (95% confidence interval,
CI: 1.7-43.4) and 7.4 (95% CI: 2.0-26.8) for infections with
versus without colonisation. Among the biologics, infec-
tions appeared less frequent with etanercept and rituximab
(Table 2).
Discussion
In the present study, the rate of infections was higher with
biologics than with non biologic DMARDs (odds ratio 8.7,
95% CI 1.7-43.4). The second factor predicting infections
was sputum colonisation (odds ratio, 7.4, 95% CI 2.0-26.8).
The increased risk of infectious events during biologic
treatment has been previously described but the originality
of this study is to analyse infections in rheumatic patients
with a concomitant condition, i.e., bronchiectasis which is
frequent in chronic rheumatic disorders.
First, because of the high reported prevalence of bronch-
iectasis in RA, and because of the infectious risk incurred
with biologics in case of bronchiectasis, the present results
suggest systematic clinical screening for bronchiectasis
before introduction of a biologic. In case of evocative
respiratory symptoms related to bronchiectasis after clini-
cal questioning and examination, screening with a high
resolution computed tomography may be indicated. Sys-
tematic high resolution computed tomography scans
Table 1 Baseline characteristics of 47 patients followed-up in one center for a rheumatic disease necessitating DMARD
and/or biologic therapy, and with definite bronchiectasis
All patients
(N = 47)
Rheumatoid
Arthritis
(N = 40)
Others diagnosis
(N = 7)
Mean age (SD) [range], years 64.1 (9.1)
[38;78]
65.8 (7.9) [43;78] 54.4 (9.7) [38;67]
Sex N (%) female 33 (70.2) 30 (75.0) 3 (42.9)
Mean disease duration of rheumatic disease at first follow up (SD) [range],
years
10.7 (8.8)
[1;43]
11.5 (8.9)
[1;43]
6 (7.2)
[1;19]
Disease duration of bronchiectasis at first follow up, years, mean (SD), [range] 6.4 (15.9)
[0;68]
7.5 (17.3)
[0;68]
1.7 (3.7)
[0;10]
NA: not applicable
Percentages are presented as % of available data
Table 2 Lower respiratory tract infections in bronchiectasis concomitant to inflammatory diseases, according to the
rheumatic disease-modifying treatment
All
treatments
Non-biologic
DMARDs
Biologic
DMARDs
Etanercept Adalimumab Infliximab Abatacept Rituximab
N periods of treatment of the
rheumatologic disease
98 40 58 19 4 12 10 9
Total N infections 93 16 77 13 3 34 23 4
N patient-years of follow-up 194 98 96 33 1 30 17 12
N infections per patient-year,
mean (SD) [95% CI]
0.8 (1.4)
[0-3.6]
0.2 (0.5)
[0-1.2]
1.2 (1.6)
[0-4.3]
0.8 (1.4)
[0-3.5]
2.3 (2.1)
[0-6.4]
1.9 (1.6)
[0-5.0]
1.9 (1.9)
[0-5.6]
0.3 (0.7)
[0-1.7]
One patient was treated by anakinra ans is not detailed in the table
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pulmonary symptoms cannot be supported to date
because our data are not strong enough to support such a
position. This hypothesis should be discussed after further
research on the natural history of asymptomatic bronch-
iectasis associated to chronic inflammatory rheumatic dis-
eases. Indeed, if an infectious risk was confirmed to be
increased in these patients, high resolution computed
tomography scans should be discussed in each patient
before introduction of biologics.
The second important implication of this work concerns
treatment choices in patients with a rheumatic disease and
concomitant bronchiectasis. These results suggest that
patients with chronic inflammatory rheumatic disease and
concomitant bronchiectasis should be preferentially trea-
ted with non biologic DMARDs, rather than biologics,
where the rheumatologic situation makes such a choice
acceptable. When biologics are necessary, considerations
on infections are important to take into account. Etaner-
cept might currently be the biologic to consider first in
patients with concomitant bronchiectasis. Indeed in the
present study, among biologics, etanercept and rituximab
appeared to lead to less infection than other biologics.
Less data are available for infections during rituximab
treatment [3,6] but from a physiological point of view, this
immunosuppressive drug probably also increase the risk of
infections. Indeed, several studies of rituximab [26,27]
indicated a slightly higher infection rate in treated patients;
the most common infections were upper and lower
respiratory tract infections, nasopharyngitis and bronchitis.
However the sample size is small and cannot demonstrate
any differences between molecules in a same therapeutic
class but other larger studies have indicated seemingly
lower rates of infections with etanercept [28]. In any case,
whatever the treatment choice, respiratory tract infections
should be carefully monitored in these patients.
In the present study, bacteriologic colonisation was an
independent predictive factor of lower respiratory tract
infections. This finding is consistent with previous reports
showing bacteriologic colonisation as a predictive factor of
lower respiratory tract infections in the following year for
patients with chronic obstructive pulmonary disease (odds
ratio 6.3) [29]. Therefore, these results suggest patients
with bronchiectasis should be regularly screened for colo-
nisation by sputum examinations. Indeed, knowledge of
bacteriologic colonisation may lead to different antibiotic
choices in case of infectious events. Furthermore, Pseudo-
monas colonisation should be carefully considered as it is
a predictive factor for pulmonary function decline [30], as
is the case in bronchiectasis related to cystic fibrosis
[31,32].
The infectious risk in the global population of the study
is lower than that described previously: infections in
bronchiectasis have been reported to occur with an inci-
dence of 1.5 to 7 events per patient-year [24,33,34]
whereas in the present study, the rate was 0.8 ± 1.0 infec-
tions per patient-year. Reasons for the lower rate in the
present study may be multiple. Firstly, it is possible that
the retrospective nature of the study led to an underesti-
mation of colonizations and/or of infections. It is note-
worthy that the rate of colonization was low in the present
study. However, all sputum tests performed for our
patients were carefully analysed in a tertiary-care hospital
bacteriology unit. Secondly, systematic vaccinations in our
department for pneumococcal and influenza infections
may improve airway disease control. These vaccinations
are recommended before introduction of biologics [35]
but also in patients with bronchiectasis [36]. Thus, these
findings suggest to check vaccination status in those
patients. Finally, systematic and very regular follow-up of
our patients for their rheumatic disease can contribute to
a lower rate of lower respiratory tract infections, possibly
through prescription of pulmonary rehabilitation. Indeed,
pulmonary rehabilitation is a well-established and effective
intervention for patients with bronchiectasis leading to
reductions in the incidence of acute exacerbations and
reduced health care utilisation as well as improvements in
exercise tolerance and health-related quality of life [37,38].
Conclusions of the present study should be inter-
preted with cautions because of limitations related to
the study design: the retrospective nature of the study
and the small sample size due to the low prevalence of
the disease. Along this line, comparisons between biolo-
gics should be looked at with the greatest caution.
Conclusions
This study indicates factors predicting respiratory tract
infections in patients with chronic inflammatory rheu-
matic disease associated with bronchiectasis were biologic
treatments and sputum colonisation. Considering on one
h a n dt h ep r e v a l e n c eo fb r o n c h i e c t a s i si nR A ,a n do nt h e
other hand the increase of biologics’ prescription, physi-
cians should be careful about any respiratory symptoms
before initiating biologics and use of high resolution com-
puted tomography may be warranted in certain cases. In
case of definite bronchiectasis, prescription of biologics
should be carefully weighted. In such a case, careful moni-
toring of respiratory infections is essential and should
include systematic sputum bacterial examination to search
for sputum colonisation. Larger and prospective studies
Table 3 Predictive factors of respiratory tract infections
in multivariate logistic regression
Odds Ratio (95% CI) P value
Bacteriologic colonisation 7.4 (2.0-26.8) 0.002
Treatment with biologics
(vs non biologic DMARDs)
8.7 (1.7-43.4) 0.008
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and monitoring in these patients.
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